A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline ( Sirtris, a GSK Company )
ClinicalTrials.gov Identifier:
NCT01453491
First received: October 13, 2011
Last updated: August 1, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)